Spidits
Product Launch

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

Summary

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a

Why It Matters

Broadens access to advanced AI capabilities for developers and end-users.

Track AI Developments

See model releases, funding rounds, and technical news on the live interactive timeline.

Open Live Timeline
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss | AI Timeline | Spidits | Spidits